Damage of hormonal function and bone metabolism in long-term survivors of testicular cancer

Ondrušová, Martina; Ondruš, D; Dušek, Ladislav; Spanikova, B.

doi:10.4149/neo_2009_06_473

Cited by 33 publications

(50 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hypogonadism may not only lead to fertility issues, muscle weakness, depression, loss of energy, and reduced sexual function and well being, [78][79][80][81][82] because it is also associated with increased risk of osteoporosis, 83,84 CVD, and metabolic syndrome. 27,85,86 Sprauten and colleagues 74 examined 307 Norwegian TCS treated from 1980 to 1994 who had blood samples collected at 3 time points: after orchiectomy but before further treatment, at survey I (SI;-2002, and survey II (SII; 2007-2008).…”

Section: Risksmentioning

confidence: 98%

Long-term Morbidity of Testicular Cancer Treatment

Fung

Fosså

Williams

et al. 2015

Urologic Clinics of North America

View full text Add to dashboard Cite

Section: Risksmentioning

confidence: 98%

Long-term Morbidity of Testicular Cancer Treatment

Fung

Fosså

Williams

et al. 2015

Urologic Clinics of North America

View full text Add to dashboard Cite

“…The decreases in BMD were most typically seen in the lumbar spine and femoral neck. The effect of orchiectomy is less well studied, but patients receiving orchiectomy have higher rates of osteoporosis and osteopenia compared to population controls, and low testosterone levels in these patients were significantly associated with lower BMD [121, 122]. …”

Section: Comparison Of Bone Quality Between Hypergonadotropic and mentioning

confidence: 99%

Male Hypogonadism and Osteoporosis: The Effects, Clinical Consequences, and Treatment of Testosterone Deficiency in Bone Health

Golds

Houdek

Arnason

2017

International Journal of Endocrinology

View full text Add to dashboard Cite

It is well recognized that bone loss accelerates in hypogonadal states, with female menopause being the classic example of sex hormones affecting the regulation of bone metabolism. Underrepresented is our knowledge of the clinical and metabolic consequences of overt male hypogonadism, as well as the more subtle age-related decline in testosterone on bone quality. While menopause and estrogen deficiency are well-known risk factors for osteoporosis in women, the effects of age-related testosterone decline in men on bone health are less well known. Much of our knowledge comes from observational studies and retrospective analysis on small groups of men with variable causes of primary or secondary hypogonadism and mild to overt testosterone deficiencies. This review aims to present the current knowledge of the consequences of adult male hypogonadism on bone metabolism. The direct and indirect effects of testosterone on bone cells will be explored as well as the important differences in male osteoporosis and assessment as compared to that in females. The clinical consequence of both primary and secondary hypogonadism, as well as testosterone decline in older males, on bone density and fracture risk in men will be summarized. Finally, the therapeutic options and their efficacy in male osteoporosis and hypogonadism will be discussed.

show abstract

“…Primary hypogonadism, defined as low total testosterone levels with elevated luteinising hormone (LH) occurs in up to 20% of testicular cancer survivors [1]. As the majority of men with testicular cancer are young with excellent long-term survival, hypogonadism and fertility are issues of concern, often related to treatment intensity.…”

Section: University Of Sydney Sydney Nsw Australiamentioning

confidence: 99%

Invited Presentations and Oral Abstracts

Horvath¹,

Lin²,

Mahon³

et al. 2017

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

One of the key recent advances in our understanding of urothelial carcinoma of the bladder has been the identification of molecular subtypes based primarily on RNA expression. A five-category taxonomy was reported first in 2012, which was followed by three separate classification systems described in early 2014 that established bladder cancer subtyping as critical to further molecular characterization of bladder cancer, and as potentially clinically relevant for novel therapeutics and biomarker development.There are significant commonalities between all of the bladder cancer subtyping systems. In general terms, they all divide tumors into luminal and basal subtypes, as has been long established in breast cancer. Each classification system differentiates additional subtypes within luminal and basal tumors. Key molecular underpinnings for each subtype have been described, and these provide a framework for further delineation of the molecular mechanisms that are critical to bladder cancer development and progression. Immunologic features play a central role in the subtyping, and immune markers alone can be used to recapitulate the molecular classification.The clinical implications of molecular subtyping of bladder cancer pertain to prognostication and prediction of response to therapy. Choi et al. (Cancer Cell, 25, 152-165, 2014) were the first to identify that the subtypes predicted survival independent of therapy and also predicted response to neoadjuvant chemotherapy. We developed a single patient classifier that demonstrated that patients with basal tumors had the greatest benefit from neoadjuvant cisplatin-based chemotherapy. Further validation is however required before this can be used in clinical practice. Two groups have reported disparate results linking subtypes to response to immunotherapy in the metastatic setting, and more work is also required in this domain. abs#2 CATCHING-UP: OPPORTUNITIES AND CHALLENGES FOR KIDNEY CANCER BIOMARKERS TO ENABLE TRANSLATIONAL RESEARCH Craig Gedye 1 1 Calvary Mater Newcastle, Waratah, NSW, AustraliaPrecision medicine to individualize cancer management options depends on discriminatory biomarkers to inform patients and their clinicians. Beyond histology and clinical biomarkers, these are largely lacking in kidney cancer. Despite these challenges, kidney cancer is catching up to other cancers with an evolving array of biomarkers including clinical, proteomic and nucleic acid based predictors. This review will briefly summarise biomarkers in routine use, but focus on developing assays that have the potential to illuminate myriad clinical situations in the management of kidney cancer that will benefit from predictive and/or prognostic discriminators. We will particularly focus on predictors of immunotherapy benefit and resistance, and strategies to improve targeted therapy by use of clinical biomarkers. (1), and certain biomarkers may be characteristic as kidney progresses from a pre-malignant to malignant state. We assess magnetic resonance spectroscopy (MRS) as a pre-...

show abstract

Damage of hormonal function and bone metabolism in long-term survivors of testicular cancer

Cited by 33 publications

References 12 publications

Long-term Morbidity of Testicular Cancer Treatment

Long-term Morbidity of Testicular Cancer Treatment

Male Hypogonadism and Osteoporosis: The Effects, Clinical Consequences, and Treatment of Testosterone Deficiency in Bone Health

Invited Presentations and Oral Abstracts

Contact Info

Product

Resources

About